FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064826358> ?p ?o ?g. }

• W2064826358 endingPage "1069" @default.
• W2064826358 startingPage "1063" @default.
• W2064826358 abstract "ObjectiveCilnidipine is a novel, long-action L/N-type dihydropyridine calcium channel blocker that has recently been used for antihypertensive therapy. We investigated the vasorelaxation effect of cilnidipine with regard to its calcium channel blockage and nitric oxide-cyclic guanosine monophosphate-dependent mechanism in human internal thoracic artery.MethodsFresh human internal thoracic arteries taken from discarded tissues of patients undergoing coronary artery bypass surgery were studied. Concentration-relaxation curves for cilnidipine in comparison with nifedipine were studied. The expression level of endothelial nitric oxide synthase mRNA was assayed by quantitative real-time polymerase chain reaction, and the phosphorylation of endothelial nitric oxide synthase at Ser1177 was determined by Western blotting analysis.ResultsCilnidipine and nifedipine caused nearly full relaxation in potassium-precontracted internal thoracic artery. Pretreatment with cilnidipine at the clinical plasma concentration significantly depressed the maximal contraction. Endothelium denudation (47.7% ± 7.0%, P < .05) and inhibition of endothelial nitric oxide synthase (48.6% ± 6.1%, P < .05) or guanylate cyclase (41.6% ± 3.8%, P < .01) significantly reduced the cilnidipine-induced endothelium-dependent relaxation (73.9% ± 6.4%). Cilnidipine increased the expression of endothelial nitric oxide synthase mRNA by 42.4% (P < .05) and enhanced phosphorylation level of endothelial nitric oxide synthase at Ser1177 by 37.0% (P < .05).ConclusionsThe new generation of calcium channel antagonist cilnidipine relaxes human arteries through calcium channel antagonism and increases production of nitric oxide by enhancement of endothelial nitric oxide synthase. The dual mechanisms of cilnidipine in human arteries demonstrated in this study may prove particularly important in vasorelaxing therapy in cardiovascular diseases. Cilnidipine is a novel, long-action L/N-type dihydropyridine calcium channel blocker that has recently been used for antihypertensive therapy. We investigated the vasorelaxation effect of cilnidipine with regard to its calcium channel blockage and nitric oxide-cyclic guanosine monophosphate-dependent mechanism in human internal thoracic artery. Fresh human internal thoracic arteries taken from discarded tissues of patients undergoing coronary artery bypass surgery were studied. Concentration-relaxation curves for cilnidipine in comparison with nifedipine were studied. The expression level of endothelial nitric oxide synthase mRNA was assayed by quantitative real-time polymerase chain reaction, and the phosphorylation of endothelial nitric oxide synthase at Ser1177 was determined by Western blotting analysis. Cilnidipine and nifedipine caused nearly full relaxation in potassium-precontracted internal thoracic artery. Pretreatment with cilnidipine at the clinical plasma concentration significantly depressed the maximal contraction. Endothelium denudation (47.7% ± 7.0%, P < .05) and inhibition of endothelial nitric oxide synthase (48.6% ± 6.1%, P < .05) or guanylate cyclase (41.6% ± 3.8%, P < .01) significantly reduced the cilnidipine-induced endothelium-dependent relaxation (73.9% ± 6.4%). Cilnidipine increased the expression of endothelial nitric oxide synthase mRNA by 42.4% (P < .05) and enhanced phosphorylation level of endothelial nitric oxide synthase at Ser1177 by 37.0% (P < .05). The new generation of calcium channel antagonist cilnidipine relaxes human arteries through calcium channel antagonism and increases production of nitric oxide by enhancement of endothelial nitric oxide synthase. The dual mechanisms of cilnidipine in human arteries demonstrated in this study may prove particularly important in vasorelaxing therapy in cardiovascular diseases." @default.
• W2064826358 created "2016-06-24" @default.
• W2064826358 creator A5016150066 @default.
• W2064826358 creator A5021520609 @default.
• W2064826358 creator A5026868249 @default.
• W2064826358 creator A5032974846 @default.
• W2064826358 creator A5033244066 @default.
• W2064826358 creator A5047336215 @default.
• W2064826358 creator A5048288156 @default.
• W2064826358 creator A5064231427 @default.
• W2064826358 date "2011-04-01" @default.
• W2064826358 modified "2023-10-14" @default.
• W2064826358 title "Dual actions of cilnidipine in human internal thoracic artery: Inhibition of calcium channels and enhancement of endothelial nitric oxide synthase" @default.
• W2064826358 cites W1089402 @default.
• W2064826358 cites W1616865606 @default.
• W2064826358 cites W1967524169 @default.
• W2064826358 cites W1991912708 @default.
• W2064826358 cites W1993460732 @default.
• W2064826358 cites W2000446588 @default.
• W2064826358 cites W2004378358 @default.
• W2064826358 cites W2014198512 @default.
• W2064826358 cites W2024986782 @default.
• W2064826358 cites W2042847451 @default.
• W2064826358 cites W2091331901 @default.
• W2064826358 cites W2091637333 @default.
• W2064826358 cites W2102538129 @default.
• W2064826358 cites W2103250636 @default.
• W2064826358 cites W2120186379 @default.
• W2064826358 cites W2127207456 @default.
• W2064826358 cites W2145899271 @default.
• W2064826358 cites W2150748626 @default.
• W2064826358 cites W4234756224 @default.
• W2064826358 cites W4254741601 @default.
• W2064826358 cites W4294567934 @default.
• W2064826358 doi "https://doi.org/10.1016/j.jtcvs.2010.01.048" @default.
• W2064826358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20599230" @default.
• W2064826358 hasPublicationYear "2011" @default.
• W2064826358 type Work @default.
• W2064826358 sameAs 2064826358 @default.
• W2064826358 citedByCount "20" @default.
• W2064826358 countsByYear W20648263582012 @default.
• W2064826358 countsByYear W20648263582013 @default.
• W2064826358 countsByYear W20648263582016 @default.
• W2064826358 countsByYear W20648263582017 @default.
• W2064826358 countsByYear W20648263582018 @default.
• W2064826358 countsByYear W20648263582020 @default.
• W2064826358 countsByYear W20648263582021 @default.
• W2064826358 countsByYear W20648263582022 @default.
• W2064826358 countsByYear W20648263582023 @default.
• W2064826358 crossrefType "journal-article" @default.
• W2064826358 hasAuthorship W2064826358A5016150066 @default.
• W2064826358 hasAuthorship W2064826358A5021520609 @default.
• W2064826358 hasAuthorship W2064826358A5026868249 @default.
• W2064826358 hasAuthorship W2064826358A5032974846 @default.
• W2064826358 hasAuthorship W2064826358A5033244066 @default.
• W2064826358 hasAuthorship W2064826358A5047336215 @default.
• W2064826358 hasAuthorship W2064826358A5048288156 @default.
• W2064826358 hasAuthorship W2064826358A5064231427 @default.
• W2064826358 hasBestOaLocation W20648263581 @default.
• W2064826358 hasConcept C120770815 @default.
• W2064826358 hasConcept C126322002 @default.
• W2064826358 hasConcept C134018914 @default.
• W2064826358 hasConcept C2776992346 @default.
• W2064826358 hasConcept C2777622882 @default.
• W2064826358 hasConcept C2778010969 @default.
• W2064826358 hasConcept C2778326061 @default.
• W2064826358 hasConcept C2779066535 @default.
• W2064826358 hasConcept C2908688039 @default.
• W2064826358 hasConcept C42219234 @default.
• W2064826358 hasConcept C519063684 @default.
• W2064826358 hasConcept C519581460 @default.
• W2064826358 hasConcept C71924100 @default.
• W2064826358 hasConcept C85520022 @default.
• W2064826358 hasConcept C98274493 @default.
• W2064826358 hasConceptScore W2064826358C120770815 @default.
• W2064826358 hasConceptScore W2064826358C126322002 @default.
• W2064826358 hasConceptScore W2064826358C134018914 @default.
• W2064826358 hasConceptScore W2064826358C2776992346 @default.
• W2064826358 hasConceptScore W2064826358C2777622882 @default.
• W2064826358 hasConceptScore W2064826358C2778010969 @default.
• W2064826358 hasConceptScore W2064826358C2778326061 @default.
• W2064826358 hasConceptScore W2064826358C2779066535 @default.
• W2064826358 hasConceptScore W2064826358C2908688039 @default.
• W2064826358 hasConceptScore W2064826358C42219234 @default.
• W2064826358 hasConceptScore W2064826358C519063684 @default.
• W2064826358 hasConceptScore W2064826358C519581460 @default.
• W2064826358 hasConceptScore W2064826358C71924100 @default.
• W2064826358 hasConceptScore W2064826358C85520022 @default.
• W2064826358 hasConceptScore W2064826358C98274493 @default.
• W2064826358 hasIssue "4" @default.
• W2064826358 hasLocation W20648263581 @default.
• W2064826358 hasLocation W20648263582 @default.
• W2064826358 hasOpenAccess W2064826358 @default.
• W2064826358 hasPrimaryLocation W20648263581 @default.
• W2064826358 hasRelatedWork W1509822090 @default.
• W2064826358 hasRelatedWork W194382415 @default.
• W2064826358 hasRelatedWork W1969670103 @default.
• W2064826358 hasRelatedWork W2021330452 @default.

• next